Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test
In This Article:
Shares of Bristol Myers Squibb tumbled Wednesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Shares of Bristol Myers Squibb tumbled Wednesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study.